Eli Lilly considers copying Novo Nordisk's semaglutide branding strategy
Novo Nordisk branded the GLP-1 analog, semaglutide, under different names for respective treatments of obesity and diabetes. Now, Eli Lilly is chewing over a similar move for tirzepatide.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Novo Nordisk has a history of marketing drugs under different names for treatments of obesity and diabetes, respectively. Novo Nordisk's biggest competitor, Eli Lilly, is now pondering a similar move, writes industry media Fiercepharma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
Eli Lilly submits tirzepatide for approval in US and EU
For subscribers
.jpg&w=384&q=75)
